MAXYGEN INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-11-05: Form 8-K; Period of report 2009-10-30; Description 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 2.02.
- 2009-09-28: Form 8-K; Period of report 2009-09-22; Description 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 1.01.
- 2009-09-21: Form 8-K; Period of report 2009-09-18; Description 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 1.01.
- 2009-08-06: Form 8-K; Period of report 2009-08-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-11-05 | 8-K | 2009-10-30 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On November 5, 2009, Maxygen, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine month periods ended September 30, 2009. 5.02 On October 30, 2009, the Board of Directors of the Company established the termination date for the employment of Dr. Elliot Goldstein, the former Chief Operating Officer of the Company, who ceased employment with the Company as of October 30, 2009. | d8k.htm |
| 2009-09-28 | 8-K | 2009-09-22 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 On September 22, 2009, the Board of Directors (the “Board”) of Maxygen, Inc. (the “Company”) approved an amendment to the Consulting Agreement between the Company and Waverley Associates, Inc. (“Waverley”), dated April 1, 2006, as amended (the “Consulting Agreement”). 5.02 As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2009, Dr. Russell Howard, Chief Executive Officer of the Company and a member of the Board, delivered his contingent resignation from the Board on July 17, 2009, with such resignation to take effect upon his termination as Chief Executive Officer of the Company. 8.01 On September 22, 2009, the Board authorized and approved special one-time grants of equity awards under the 2006 Plan to Mr. Stein and each non-employee member of the Board. | d8k.htm |
| 2009-09-21 | 8-K | 2009-09-18 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 5.02 In connection with the Closing of the Transactions on September 18, 2009, Grant Yonehiro’s position as chief business officer of the Company terminated. 8.01 The Company held its annual meeting of stockholders (the “Annual Meeting”) on September 17, 2009. | d8k.htm |
| 2009-08-06 | 8-K | 2009-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2009, Maxygen, Inc. issued a press release announcing its financial results for the three months ended June 30, 2009. | d8k.htm |
| 2009-07-17 | 8-K | 2009-07-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 16, 2009, M.R.C. Greenwood, Ph.D., notified the Chairman of the Board of Directors (the “Board”) of Maxygen, Inc. (the “Company”) that she would not be standing for re-election when her term expires at our 2009 Annual Meeting of Stockholders. | d8k.htm |
| 2009-07-01 | 8-K | 2009-06-30 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On June 30, 2009, in connection with the Transaction, the Company entered into various compensation arrangements (described below) that are contingent upon the Closing. | d8k.htm |
| 2009-05-11 | 8-K | 2009-05-07 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On May 11, 2009, Maxygen, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2009. 8.01 On May 7, 2009, the Company issued a press release announcing that it has entered into an agreement with Cangene Corporation under which it has granted Cangene an option to obtain an exclusive license to Maxygen’s proprietary MAXY-G34 protein therapeutic for use in treating acute radiation syndrome (ARS). | d8k.htm |
| 2009-02-10 | 8-K | 2009-02-10 | 2.02 Results of Operations and Financial Condition | 2.02 On February 10, 2009, Maxygen, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2008. | f51396e8vk.htm |